Advances of Artificial Intelligence in Anti-Cancer Drug Design: A Review of the Past Decade

被引:38
|
作者
Wang, Liuying [1 ]
Song, Yongzhen [1 ]
Wang, Hesong [1 ]
Zhang, Xuan [1 ]
Wang, Meng [1 ]
He, Jia [1 ]
Li, Shuang [1 ]
Zhang, Liuchao [1 ]
Li, Kang [1 ]
Cao, Lei [1 ]
机构
[1] Harbin Med Univ, Sch Publ Hlth, Dept Biostat, Harbin 150081, Peoples R China
基金
中国国家自然科学基金;
关键词
artificial intelligence; machine learning; neoplasms; drug design; databases; GENERATIVE MODEL; DISCOVERY; NETWORK; PREDICTION; INHIBITOR; RESISTANCE; FRAMEWORK; CANCERS;
D O I
10.3390/ph16020253
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Anti-cancer drug design has been acknowledged as a complicated, expensive, time-consuming, and challenging task. How to reduce the research costs and speed up the development process of anti-cancer drug designs has become a challenging and urgent question for the pharmaceutical industry. Computer-aided drug design methods have played a major role in the development of cancer treatments for over three decades. Recently, artificial intelligence has emerged as a powerful and promising technology for faster, cheaper, and more effective anti-cancer drug designs. This study is a narrative review that reviews a wide range of applications of artificial intelligence-based methods in anti-cancer drug design. We further clarify the fundamental principles of these methods, along with their advantages and disadvantages. Furthermore, we collate a large number of databases, including the omics database, the epigenomics database, the chemical compound database, and drug databases. Other researchers can consider them and adapt them to their own requirements.
引用
收藏
页数:18
相关论文
共 50 条